Activities

B-Cell Lymphomas are a heterogeneous group of blood cancers that usually respond to treatment but often eventually relapse, conferring to patients a dismal prognosis. This translational research group is working on molecular biomarkers investigation in the context of B-cell lymphoma clinical trials, mainly led by the Fondazione Italiana Linfomi (FIL). Main interests of this group are: identification of baseline prognostic and predictive biomarkers, minimal residual disease (MRD) monitoring, and implementation of non-invasive diagnostic tools (i.e. “liquid biopsy”) in mantle cell lymphoma, follicular lymphoma and Waldenström macroglobulinemia. Main technologies employed are quantitative-Real Time PCR, Droplet Digital PCR and Next Generation Sequencing to target both genomic rearrangements (e.g. immunoglobulin VDJ, Bcl1/IGH, Bcl2/IGH) and mutations (e.g. MYD88, TP53 and others). Finally, as the laboratory involves a recognized collaboration with biomedical engineers, projects on medical informatics applied on translational clinical trials are strongly supported

Group

• Dott. Ladetto Marco (MD, RTI)
• Dott. Ferrero Simone (PI)
• Dott.ssa Alessandria Beatrice (Biotecnologa, borsista)
• Dott. Clerico Michele (MD, specializzando)
• Dott.ssa Cavallo Federica (MD, RTI)
• Dott.ssa Dogliotti Irene (MD, borsista)
• Dott.ssa Drandi Daniela (biotecnologa, PhD, TdR)
• Dott.ssa Ferrante Martina (biotecnologa, PhD student)
• Dott.ssa Genuardi Elisa (Biotecnologa, PhD, assegnista di ricerca)
• Dott. Ghislieri Marco (Ingegnere Biomedico, PhD student Polito, , collaboratore)
• Dott. Grimaldi Daniele (MD, specializzando)
• Dott.ssa Mantoan Barbara (Biologa, borsista)
• Dott. Palumbo Luca (Data Manager, Borsista)
• Dott. Zaccaria Gian Maria (Ingegnere Biomedico, PhD, collaboratore)